Anemia is a condition in which the body does not have enough healthy red blood cells. Red blood cells provide oxygen to body tissues.
FDA APPROVES OMONTYS FOR ANEMIC KIDNEY PATIENTS In March 2012 Affymax Inc. won U.S. approval for Omontys, a competitor to Amgen Inc.’s anemia treatments that have been the only options for patients with loss of kidney function for more than 20 years.
The Food and Drug Administration cleared Omontys, known as peginesatide, for patients with chronic kidney disease on dialysis. The drug will be Palo Alto, California-based Affymax’s first marketed product.
“There has been and continues to be a lot of interest across the board from dialysis providers,” John Orwin, chief executive officer for Affymax, said.
Approval of the drug -- intended to be used once a month instead of as often as three times a week for Amgen’s Epogen -- may save money for Medicare, the U.S. health program for the elderly and disabled. Peginesatide may generate as much as $700 million in peak sales by 2017 according to an analyst.
Amgen has a monopoly right now and that’s not ideal because it’s occurred for two decades. Small and medium dialysis centers are price sensitive. Peginesatide would be the choice for these dialysis providers.
Dialysis removes toxins from the blood when kidneys can’t.